High Dose and Delayed Treatment with Bile Acids Ineffective in RML Prion-Infected Mice.
High Dose and Delayed Treatment with Bile Acids Ineffective in RML Prion-Infected Mice.
Antimicrob Agents Chemother. 2018 May 21;:
Authors: Norman G, Campeau J, Sim VL
Abstract
Prion diseases are a group of neurodegenerative diseases associated with the misfolding of the cellular prion protein (PrPC) into the infectious form (PrPSc). There are currently no treatments for prion disease. Bile acids have the ability to protect hepatocytes from apoptosis and are neuroprotective in animal models of other protein folding neurodegenerative diseases including Huntington's, Parkinson's, and Alzheimer's disease. Importantly, bile acids are approved for clinical use in patients with cirrhosis, and have recently been shown to be safe and possibly effective in pilot trials of patients with amyotrophic lateral sclerosis (ALS). We previously reported that the bile acid, ursodeoxycholic acid (UDCA), given early in disease, prolonged incubation periods in male RML-infected mice. Here we expand on this result to include tauro-ursodeoxycholic acid (TUDCA) treatment trials and delayed UDCA treatment. We demonstrate that, despite a high dose of TUDCA given early in disease, there was no significant difference in incubation periods between treated and untreated cohorts, regardless of sex. In addition, delayed treatment with a high dose of UDCA resulted in a significant shortening of the average survival time for both male and female mice when compared to ...
Source: Antimicrobial Agents and Chemotherapy - Category: Microbiology Authors: Norman G, Campeau J, Sim VL Tags: Antimicrob Agents Chemother Source Type: research
More News: ALS | Alzheimer's | Bile | Brain | Chemotherapy | Cirrhosis | Huntington's Disease | Microbiology | Neurology | Parkinson's Disease